Irish medical device outsourcer Creganna-Tactx Medical said today that it agreed to acquire Precision Wire Components LLC for an unspecified amount, saying it will re-brand as Creganna Medical.
Creganna-Tactx Medical
Former Abbott exec takes the helm at Creganna-Tactx Medical | Personnel Moves
Creganna-Tactx Medical CEO Helen Ryan is preparing to pass the torch after 8 years in the corner office, with Abbott (NYSE:ABT) executive Robert "Chip" Hance slated to take the helm in September.
Irish merger brings together Creganna-Tactx and ABT Medical
Ireland-based Creganna-Tactx Medical continued to vie for its seat among top minimally invasive device makers with the acquisition of Irish compatriot ABT Medical for an undisclosed amount.
ABT’s portfolio of medical balloons includes a the longest commercially available balloon components in the industry, up to and beyond 300 mm in length, according to a press release.
Irish contract medical device designer to launch Cleveland operations
Contract medical device designer and manufacturer Creganna-Tactx Medical plans to open an office in a business incubator on Cleveland Clinic’s campus.
The Galway, Ireland-based company specializes in minimally invasive devices for a wide range of customers, including startups to the world’s leading medical device firms.
Creganna-Tactx, Boston Biomedical partner for regulatory, clinical consulting
Contract research organization Boston Biomedical Associates will now have the added staff support of Creganna-Tactx Medical.
The two companies formed a joint venture under which Creganna-Tactx customers will have access to BBA’s clinical, regulatory and quality consulting services.
PE firm buys majority stake in Creganna-Tactx Medical
A British private equity firm, Permira, agreed to buy out a majority stake in Irish medical device maker Creganna-Tactx Medical.
Permira is taking over Altaris Capital Partners LLC’s stake in Creganna-Tactx; the rest of the company’s shareholders will keep their stakes, according to a press release. The Quinn family, including chairman Ian Quinn, and company management will retain their minority interests in the firm, according to Reuters.